Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethality

The in vivo efficacy of human recombinant soluble tumor necrosis factor (TNF) receptor protein to prevent and to treat lipopolysaccharide (LPS)‐induced lethal toxicity in D‐galactosamine‐treated mice was investigated. Chimeric proteins of the receptor extracellular domains fused to the hinge region of human IgG3 were expressed in myeloma cells (rsTNFR‐hγ3). The fusion proteins had a disulfide‐bonded dimeric structure. Upon intravenous injection, their serum concentration decreased relatively slowly after an initial phase of rapid elimination. D‐galactosamine‐sensitized mice were fully protected from the toxic effects of LPS, if the animal were pretreated with rsTNFR‐hγ3 at 20 μg/animal. Partial protection was seen at significantly lower doses and when rsTNFR‐hγ3 was given up to 3 h after LPS.

[1]  G. Grau,et al.  Prevention of human TNF-induced cutaneous Shwartzmann reaction and acute mortality in mice treated with anti-human TNF monoclonal antibodies. , 1991, Clinical and experimental immunology.

[2]  J. Norton,et al.  A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice , 1991, The Journal of experimental medicine.

[3]  G. Spinas,et al.  Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. , 1991, The Journal of infectious diseases.

[4]  J. Abrams,et al.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. , 1990, Journal of immunology.

[5]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[6]  D. Wallach,et al.  Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. , 1990, The Journal of biological chemistry.

[7]  P. Vassalli,et al.  Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. , 1990, The American journal of pathology.

[8]  P. Zabel,et al.  OXPENTIFYLLINE IN ENDOTOXAEMIA , 1989, The Lancet.

[9]  J. Dayer,et al.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. , 1989, The Journal of biological chemistry.

[10]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[11]  K. Karjalainen,et al.  Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.

[12]  E. Nilsson,et al.  Isolation and characterization of a tumor necrosis factor binding protein from urine , 1989, European journal of haematology.

[13]  I. Olsson,et al.  A tumor necrosis factor binding protein is present in human biological fluids , 1988, European journal of haematology.

[14]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[15]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[16]  J. Dayer,et al.  A human inhibitor of tumor necrosis factor alpha , 1988, The Journal of experimental medicine.

[17]  H. Schreiber,et al.  Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[19]  C. Galanos,et al.  Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice , 1987, The Journal of experimental medicine.

[20]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[21]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[22]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.